Sound Pharmaceuticals Overview

  • Founded
  • 2001
Founded
  • Status
  • Private
  • Employees
  • 13
Employees
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 7

Sound Pharmaceuticals General Information

Description

Provider of a bio-pharmaceutical platform intended to develop drugs to prevent and treat hearing loss. The company's platform develops compounds designed to antagonize growth inhibitory proteins so that normally non-dividing epithelial cells within the inner ear are able to divide and have the capacity to become replacement auditory hair cells, a developmental process that does not occur in humans after birth, enabling doctors to prevent and treat various forms of hearing loss in a cost-efficient way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • 4010 Stone Way North
  • Suite 120
  • Seattle, WA 98103
  • United States
+1 (206) 000-0000

Sound Pharmaceuticals Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sound Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Debt - PPP 14-Apr-2020 000.00 Completed Generating Revenue
6. Later Stage VC (Series C2) 06-Jun-2018 00.000 000.00 000.00 Completed Generating Revenue
5. Grant 20-Mar-2017 00.00 0000 Completed Clinical Trials - Phase 2
4. Later Stage VC 15-Oct-2013 000 0000 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 29-Jun-2006 000 000 Completed Clinical Trials - Phase 2
2. Grant 19-Dec-2002 $160K $1M Completed Startup
1. Seed Round $1M $1M Completed Startup
To view Sound Pharmaceuticals’s complete valuation and funding history, request access »

Sound Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C2 0,000,000 00.000000 00 00 00 00 00 00.000
Series C-1 0,000,000 00.000000 00 00 00 00 00 00.000
Series C 0,000,000 00.000000 00 00 00 00 00 00.000
Series B 3,000,000 $0.000100 8% $1 $1 1x $1 20.73%
Series A 800,000 $0.000100 8% $0.02 $0.02 1x $0.02 5.53%
To view Sound Pharmaceuticals’s complete cap table history, request access »

Sound Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of a bio-pharmaceutical platform intended to develop drugs to prevent and treat hearing loss. The company's pla
Pharmaceuticals
Seattle, WA
13 As of 2021
000.00
000000000 - 000.00

0000000

mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
San Diego, CA
00 As of 0000
00000
000000 - 000 00000

0000000

n ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
0000 000000000
Boston, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sound Pharmaceuticals Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Otonomy Formerly VC-backed San Diego, CA 00 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 00 00000 00000000 00000
00000 0000000 Formerly VC-backed Basel, Switzerland 0 00000 000000000 00000
You’re viewing 3 of 3 competitors. Get the full list »

Sound Pharmaceuticals Executive Team (7)

Name Title Board Seat Contact Info
Jonathan Kil MD Co-Founder, President, Chief Medical Officer, Chief Executive Officer & Board Member
John Sullivan Chief Financial Officer
Eric Lynch Ph.D Co-Founder, Chief Science Officer, President, Vice President & Board Member
G. Michael Wall Ph.D Vice President, Pharmaceutical Development
Ulrich Mueller Ph.D Vice President, Business Development
You’re viewing 5 of 7 executive team members. Get the full list »

Sound Pharmaceuticals Board Members (7)

Name Representing Role Since
David Guyer MD Self Board Member & Strategic Advisor 000 0000
Eric Lynch Ph.D Sound Pharmaceuticals Co-Founder, Chief Science Officer, President, Vice President & Board Member 000 0000
Glenn Kawasaki Ph.D Self Board Member 000 0000
James Towne Sound Pharmaceuticals Board Member 000 0000
Jonathan Kil MD Sound Pharmaceuticals Co-Founder, President, Chief Medical Officer, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Sound Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sound Pharmaceuticals Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cystic Fibrosis Foundation Corporation 000 0000 000000 0
KEC Ventures Venture Capital Minority 000 0000 000000 0
Richard Hedreen Angel (individual) Minority 000 0000 000000 0
Sujal Patel Angel (individual) Minority 000 0000 000000 0
National Institute of Deafness Government 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »